ReSearch Pharmaceutical Services Inc. (“RPS”) was incorporated in Delaware on January 30, 2006 as Cross Shore Acquisition Corporation (“Cross Shore”), a blank check company formed to serve as a vehicle for the acquisition of a then unidentified operating business engaged in the delivery of business services to consumers and companies in the United States. On April 24, 2006, Cross Shore consummated an initial public offering on the Alternative Investment Market (“AIM”) of the London Stock Exchange, and on April 26, 2007, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with ReSearch Pharmaceutical Services Inc., a Pennsylvania corporation (“Old RPS”). Upon the completion of the merger with Old RPS on August 30, 2007, the combined company changed its name to ReSearch Pharmaceutical Services Inc. Prior to the merger with Old RPS, Cross Shore had no operating business other than searching for an acquisition target. Old RPS was originally incorporated under the name ReSearch Pharmaceutical Search Inc. in Pennsylvania on November 21, 1994. Old RPS changed its name to ReSearch Pharmaceutical Services Inc. on March 10, 2003. Longxia Acquisition Inc., a wholly owned subsidiary of Cross Shore, merged with and into Old RPS with Old RPS being the surviving corporation. Old RPS subsequently merged with and into a wholly-owned subsidiary of Cross Shore on August 30, 2007. As a result of this merger, Old RPS became ReSearch Pharmaceutical Services, LLC a limited liability company organized under the laws of Delaware, and Cross Shore changed its name to ReSearch Pharmaceutical Services Inc. RPS is now a holding company for, and conducts all of its operations through its wholly-owned subsidiary, ReSearch Pharmaceutical Services, LLC. On September 4, 2009, RPS delisted its common stock from AIM following approval of the delisting by the requisite number of shareholders. Trading in RPS’ warrants to purchase common stock, also listed on AIM, was suspended following delisting of the common stock, and the warrants were delisted on October 5, 2009. RPS common stock and warrants are no longer traded on AIM, but remain transferable as described in the proxy statement which was mailed to shareholders and warrant holders on July 24, 2009, and subject to applicable securities laws. The business of ReSearch Pharmaceutical Services, LLC is now the sole business of RPS. As used herein, unless the context otherwise requires or specifies, RPS, the registrant, its wholly-owned direct and indirect subsidiaries, and together with Old RPS, are referred to in this Annual Report as “we,” “us,” “our,” and the “Company.”
Company profile
Ticker
RPSE
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Icon • Syneos Health • Medpace • Incyte • Zymergen • OmniAb ...
SEC CIK
Corporate docs
IRS number
204322769
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
2 May 24
424B5
Prospectus supplement for primary offering
26 Apr 24
F-3ASR
Automatic shelf registration (foreign)
26 Apr 24
RW
Registration withdrawal request
28 Sep 11
15-12G
Securities registration termination
18 Feb 11
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Feb 11
DEFM14C
Information related to merger
25 Jan 11
PREM14C
Preliminary information related to merger
14 Jan 11
8-K
Research Pharmaceutical Services to Be Acquired by Warburg Pincus
28 Dec 10
S-1/A
IPO registration (amended)
23 Nov 10
Latest ownership filings
No filings